Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares plunged once again on Thursday after Hillary Clinton called out the company at a campaign appearance. Here is what she had to say:

This is a letter from someone who’s here. And she gave me this letter. She has to take a brand name drug. She’s been taking it since the early 1980s. At that time, back in the 1980s, for the same drug, it cost approximately $180 for 10 shots. The latest refill she received from her pharmacy was $14,729.99 for the same 10 vials. And the company is one of these companies that is absolutely gouging American consumers and patients. It’s called Valeant Pharmaceuticals. I’m going after them. We are going to stop this. This is predatory pricing. It is unjustified. It is wrong. And we’re going to make sure it is stopped.

At the end of these remarks, the Iowan crowd gave her a standing ovation, which is a fair reflection of how Americans feel about the issue.

So what exactly does this mean for Valeant?

The stars are aligned

Normally, it is very difficult to get legislation passed in Washington. But this issue has strong bipartisan support. To illustrate, in a recent survey by the Kaiser Family Foundation, 83% of Americans favour the idea of letting Medicare negotiate for lower drug prices, including 74% of Republicans.

With that kind of bipartisan support, there’s a chance of legislation even if a Republican gets elected. For what it’s worth, Donald Trump has said that Medicare should negotiate for discounted prices.

Alarmingly for Valeant, the company can’t even get any support from PhRMA, the pharmaceutical industry’s main lobby group. Back in October PhRMA posted an article on its website entitled “What makes Valeant different than innovative biopharmaceutical companies?” PhRMA noted in the article how Valeant spent only 3% of revenue on research and development in 2014 and compared the company to the much-maligned Turing Pharmaceuticals.

Is the stock still cheap enough?

There are a lot of people who still think Valeant is worth owning. To illustrate, 13 analysts rate the stock “Strong Buy” or “Buy” while only one rates the stock “Underperform,” according to Yahoo Finance. And it’s easy to see why–the company trades at a massive discount to its peers.

But let’s not forget that Valeant is the subject of a number of investigations, and we still haven’t gotten to the bottom of its relationship with Philidor. Making matters worse, the company has US$30 billion in debt, so there isn’t much room for error. In my opinion, the stock is simply too risky and there are better options for your portfolio.

A much better stock than Valeant

Exports of liquefied natural gas could be one of the best growth opportunities out there for long-term investors. And, we think we've identified the Canadian company to invest in. It's a global company with operations across nearly 20 countries and 70 locations. We like it so much, we've named it as 1 Top Stock for 2016 and Beyond. To find out why, click here now to learn how to access your FREE copy today!


Let’s not beat around the bush – energy companies performed miserably in 2015. Yet, even though the carnage was widespread, not all energy-related businesses were equally affected.

We've identified an energy company we think offers one of the best growth opportunities around. While this company is largely tied to the production of natural gas, it doesn't actually produce the gas. Instead, it provides the equipment required to get natural gas from the ground to the end user. With diversified operations around the globe, we think it's a rare find in the industry.

We like it so much, we’ve named it as 1 Top Stock for 2016 and Beyond. To find out why, simply enter your email address below to claim your FREE copy of this brand new report, "1 Top Stock for 2016 and Beyond"!

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.